3 Feb 2026 – MEDTRAC™ Strategy Update – A new Animal Health Division will be created to develop the company’s products and fast-track regulatory approval for our near-real-time monitoring solution MEDTRAC™ Health Advisor, with a business focus on the equine and canine sectors. This will provide research-grade material and expedite US/UK/European regulatory approval. This vertical market is likely to encounter less regulatory friction, allowing us to obtain FDA licensure early and then return to the human model for approval. We will initially focus on jurisdictions that are more open to innovation in human monitoring, with GCC countries and Saudi Arabia as potential options, given their focus on medtech innovation. Further details coming soon.

2 Feb 2026 — MEDTRAC™ today announced the identification of a novel remote biofeedback-based health screening and monitoring technology, provisionally named MEDTRAC™ Health Advisor, which materially extends the company’s existing multi-sourced screening and assessment capabilities. Initial internal testing has demonstrated strong concordance with established screening outputs, supporting progression to controlled in-clinic validation prior to any external release. Planned development includes integration with a local HRV patch to create a proprietary, patentable screening architecture, with the next milestone focused on delivering a live, fully automated demonstration pipeline for the technology. More

In addition to human health applications, the MEDTRAC™ platform architecture is designed to support non-human health screening use cases, including equine and canine monitoring, where early identification of physiological stress, autonomic imbalance, and performance- or welfare-related risk patterns is required. These applications reuse the same pre-diagnostic screening and pattern analysis framework, adapted for species-specific physiology, and are intended for veterinary, performance, and welfare monitoring contexts rather than medical diagnosis.

20 January — MEDTRAC™ has developed a proprietary knowledge-retention platform, the MEDTRAC™ Knowledge Surface, designed to provide rapid access to information regardless of location, document storage, or training materials for the company’s large language model, and to serve as a foundation for codifying analytical knowledge-engine rules across its projects, with references back to source documents as required for regulatory audits. These rules are both deterministic (consistent) and up to 10,000× faster than LLM-based AI models, making them suitable for real-time clinic decision support and high-volume online health screening. The platform addresses the persistent “Where did I put that information, or where did it come from?” problem by routing all relevant data to a single, structured location and enabling high-speed search with typical retrieval times of 0.2–0.5 seconds, combined with large-language-model-based discovery. This approach eliminates the need to continually retrain models on locally stored data and makes a new RULE or knowledge summary accessible to our in-house chat model within seconds. This product has been externally benchmarked against LLMs (Claude & OpenAI) and scored higher in design and architecture than Notion, the industry leader in rapid, team-based knowledge sharing. This tool will be available to the team for testing shortly. More

10th Jan 2025 – MEDTRAC™ Health Advisor Platform soft-launched. A culmination of five years of research starting in 2020. The first component of the platform provides online triage and questionnaires, serving as the entry point for most clients to the MEDTRAC™ Health Advisor. Designed to increase the capacity of medical and health service providers, reduce costs, and improve service through automated screening and pre-diagnostic testing.

The first release was launched as a POC offering a simple structure covering four core screening categories. In Version 1.02, the design has been enhanced significantly. In early testing, the latest version immediately demonstrated its potential, achieving a 10/10 screening outcome with the first online client, who was subsequently confirmed to have Lyme disease (see Jane Doe case study). The platform identified the most likely pathogens, which were confirmed by in-clinic testing one week later. This result strongly validates the technology’s direction and supports accelerating the development of the Health Advisor platform. Version 1.02 is due to be released shortly, subject to engineering changes to our infrastructure, including a transition from Windows to Linux Xubuntu as the development and server platform. Click here to learn more
The BETA 1.01 Questionnaire:- https://netlite.community/questionnaire/welcome